London, England: According to WHO’s world malaria report for 2019, there were an estimated 228 million cases of malaria in 89 countries. India accounted for 58% of the patient population, followed by Indonesia at 30% and Myanmar at 10%. India has made good progress in reducing the overall cases, but the challenge still remains.
Dengue continues to be the most rapidly spreading vector-borne viral disease globally, with an increasing number of countries at risk. It continues to pose a substantial public health risk to a country like India. There are estimated 390 million dengue virus infections globally per year.
The estimated average cost of treatment dengue remains high. Total annual cost of dengue to public healthcare system is over US$8.89 billion, and this does not include the economic costs borne by the families, which can be substantial, especially for rural communities.
Advertisement
AML Bio, Korea in partnership Harley Street Clinics of London (part of Harley Street Healthcare Group) has developed the new affordable dengue and malaria treatment drug, which it plans to start distributing across rural communities in India as an over-the-counter product in partnering with the local government agencies as well as NGOs to support individuals and families.
AML Bio and Harley Street Healthcare Group (HSHG) have jointly carried out clinician trials in several countries including of Indonesia. Harley Street officials in India have already met with the directorate of health and NITI Aayog officials along with other relevant government agencies in India to secure appropriate approvals before the launch. The company is aiming to have the product available in India soon.
Advertisement
HSHG is a diverse and consolidated healthcare business based in the heart of London with a global presence and AML Bio is a Korea-based life science R&D company.
For more information: Please visit: https://www.harleystreetgroup.ca/, and write to Sanjeev Kumar, Chief Visionary Officer at sanjeev@harleystreetgroup.ca
